As an MD-PhD, research has been a nuclear part of my career, in addition to healthcare and teaching. According to PubMed I have 169 publications (WoS H-index: 36). I have contributed in the area of primary immunodeficiencies describing for the first time the genetics and molecular basis of several pathologies, with high impact papers (PMID: 17062728, PMID: 16627752, PMID: 21546492). I co-author a patent of a siRNA-based therapy for Autoimmune Lymphoproliferative Syndrome (ES2547471). I have also significantly contributed in the field of Solid Organ Transplantation (Tx) Immunology by analyzing the impact of anti-HLA and -nonHLA antibodies in the evolution of grafts. I highlight the first demonstration of the deleterious effect of HLA incompatibility and Luminex-detected-preformed antibodies on the evolution of liver Tx (PMID: 18383092, D1), which had a strong impact in liver Tx area and 95 citations so far. Thanks to a ISCIII grant I moved to P.S. Heeger's Tx Immunology lab at the Mount Sinai School of Medicine (2008-2010, 24 months). I worked to elucidate the role of complement on Treg cell biology and effect on Tx tolerance and published results in high impact journals (J Exp Med, PMID: 23382542, and J Clin Invest, PMID: 22585573). Back to HU12O I was officially appointed Head of Service and Associate Professor of Immunology at UCM. Since 2010 I am also director of the research group "Immunodeficiencies and Transplant Immunology", in Instituto de Investigación Sanitaria (Imas12). Between 2010-2015 I focused on studying the immunology of intestinal Tx (ITx). We showed for the first time the role of innate lymphoid cells (ILC), which had been recently discovered, in the ITx evolution (published in American Journal of Transplantation, AJT, number 1 journal in the field, PMID: 26317573) and proposed a transcriptomic signature predicting graft stability (PMID: 28843648). Aside to my independent competitive projects and contracts with the industry, I have been co-IP of several competitively funded consortia in national (Project of Excelence in Transplantation, ISCIII, 2013) and regional calls (NIETO project, Com. De Madrid 2017, see below). We described the role of minor immune cell populations (Tfh cells, Breg, MDSC) on the evolution of renal grafts and results were published in high-impact journals in the area of Tx, with several papers in journal number 1, AJT (PMID: 29947147, PMID: 34153157). Regarding research on MDSC (myeloid-derived suppressor cells) I was a member of the European Mye-Euniter COST Action (2016-2019). I have published >30 papers on COVID-19. My group was pioneer in defining a mortality predictive model (MPM), published in Journal of Allergy and Clinical Immunology (IF:11.4, D1 in Immunology journals) with 146 citations so far (PMID: 32710975). The MPM was independently confirmed in new cohorts in a multicentric study and published in the same journal (PMID: 33662370). We implemented an ELISPOT to analyse the T cell response against SARS-CoV-2 with extensive technical validation, and pioneered analysis on the response to natural infection and vaccination, in immune-competent (PMID: 34962970, PMID: 36059485) and immune-deficient (PMID: 34787773, PMID: 35869848) subjects. Both MPM and ELISPOT were intellectual-protected in Safe Creative. I participated in national and worldwide consortia which discovered the genetics and the role of anti-type I IFN antibodies in COVID-19, co-authoring papers in Science (PMID: 32972995, PMID: 32972996, both >1000 citations). We developed the dqTACT test to quantify anti-SARS-CoV-2 cellular immunity (published in Nature Biotech, PMID: 35697804, patented and commercialised by the UK company Hyris). Our outstanding work in COVID-19 was key to include our group in the newly created CIBERINFEC. I have been a member of the Board for Clinical Trials in HU12O (3 years), and Project Manager in Agencia Estatal de Investigación (Infection, immunity and New Therapies section, 4 years). I have directed 14 Doctoral Thesis (2 “extraordinary award”). I regularly evaluate projects and papers in international journals.